BSE: 542918
Gian Life Care Limited
Provides diagnostic services through its own diagnostic centres and manages hospital laboratories under long-term contracts. Based in Kanpur and listed on BSE, it signed a five-year Hospital Lab Management Services Agreement with Brahma Hospital (HUF), a multi-specialty hospital in Roorkee, Uttarakhand, effective March 1, 2026, which is expected to add approximately Rs 1 crore in annual revenue and Rs 18-20 lakhs in net profit per year. The company is also operationalising new diagnostic centres on a pan-India basis. Standalone revenue from operations stood at Rs 663.10 lakhs in FY25, down from Rs 1,311.98 lakhs in FY24. Other operating expenses form the largest cost line at 59.1% of revenue, followed by materials at 18.1% and depreciation at 9.5%, while employee costs account for 8.9%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Diagnostic services, Hospital lab management. Diagnostic services with both owned centres and contracted hospital lab management
Exhibit 1: Financial summary, FY22–FY25 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 16 | 12 | 13 | 7 |
| EBITDA (ex other income) | — | 2 | 6 | 1 |
| margin % | — | 15.3 | 46.3 | 13.8 |
| Owners' profit | — | 0 | 0 | 0 |
| EPS, as reported (₹) | 4.23 | 1.03 | 4.02 | 0.04 |
| ROE % · ROCE % | — · 38.4 | 7.0 · 11.6 | 21.5 · 27.5 | (0.2) · 2.4 |
| Debt / equity (x) | — | 0.30 | 0.25 | 0.30 |
| Cash from operations | 6 | 2 | 1 | 0 |
| Capex | — | (2) | (1) | 0 |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 5 | 2 | 2 | 1 | 1 | 1 | 1 |
| Profit before tax | 2 | 3 | 0 | 0 | (1) | 0 | (1) | 0 |
| Net profit | 2 | 2 | 0 | 0 | (1) | 0 | (1) | 0 |
| EPS (₹) | 1.50 | 2.07 | 0.09 | 0.12 | 0.59 | 0.05 | 0.50 | 0.10 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 32,213 | 46.3 | 12.68 | 37.5 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 14,838 | 79.1 | 15.50 | 41.4 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 11,341 | 23.4 | 7.44 | 27.1 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 7,871 | 28.9 | 13.43 | 28.7 | 27.8 | 33.2 | 10.9 | 33.9 |
| NEPHROCARE HEALTH SERV L | 6,301 | 65.1 | 5.64 | 24.9 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,628 | 16.7 | 1.66 | 8.3 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,621 | 45.3 | 6.66 | 16.4 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,170 | 19.5 | 3.53 | 13.8 | 18.1 | 22.5 | (8.9) | 52.6 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 3.4 | 23.4 | 1 of 25 | 100% |
| P/B | 0.2 | 2.0 | 1 of 24 | 100% |
| ROCE | (2.1) | 6.1 | 25 of 29 | 14% |
| ROE | (2.4) | 6.0 | 21 of 24 | 13% |
| Debt / Equity | 0.3 | 0.1 | 16 of 23 | 32% |
| EBITDA margin | 29.8 | 25.6 | 9 of 24 | 65% |
| Revenue growth | (42.3) | 20.8 | 24 of 25 | 4% |
| Profit growth | (12.0) | 22.0 | 16 of 25 | 38% |
| Market cap | 4 | 34 | 30 of 30 | 0% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 21 Apr 2026 · Reg 74(5) demat certificate filed with BSE for Q4 FY26 | compliance | minimal | — | — |
| 4 Mar 2026 · Dear Sir/Maam, The Company has entered into Hospital lab Management Services Agreement with M/s. Brahma Hospital (HUF). Detailed intimation is attached. Regards Gian Life Care Limited | business updates | medium | — | — |
| 14 Feb 2026 · Quarterly Results December 2025 | results | high | — | — |
| 14 Feb 2026 · Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, .... | results | high | — | — |
| 9 Feb 2026 · Gian Life Care Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve As per the captioned subject, .... | results | low | — | — |
| 28 Jan 2026 · Dear Sir/ Maam, Please find attached herewith Unaudited Standalone and Consolidated Financial Results for the quarter/ half year ended September 30, 2025. Kindly take the same on .... | results | high | — | — |
| 28 Jan 2026 · Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, .... | results | high | — | — |
| 24 Jan 2026 · Gian Life Care Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2026 ,inter alia, to consider and approve As per the captioned subject, .... | results | low | — | — |
| 21 Jan 2026 · Gian Life Care Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2026 ,inter alia, to consider and approve As per the captioned subject, .... | results | low | — | — |
| 21 Jan 2026 · Please find attached herewith Certificate under regulation 74(5) for the Quarter ended December 31, 2025. | compliance | minimal | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.